Trial reportDrug and alcohol dependence2010
A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period.
Trial report in Drug and alcohol dependence, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta-analysis.Addiction (Abingdon, England) · 2026Pooled it
- Predictors of cocaine use disorder treatment outcomes: a systematic review.Systematic reviews · 2024Pooled it
- Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis.Journal of general internal medicine · 2019Pooled it
- Mixed amphetamine salts-extended release (MAS-ER) as a behavioral treatment augmentation strategy for cocaine use disorder: A randomized clinical trial.Experimental and clinical psychopharmacology · 2024Trial
- Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Trial
- Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial.Molecular psychiatry · 2017Trial
- Gender differences in clinical outcomes for cocaine dependence: randomized clinical trials of behavioral therapy and disulfiram.Drug and alcohol dependence · 2014Trial
- Multimodal predictive modeling of individual treatment outcome in cocaine dependence with combined neuroimaging and behavioral predictors.Drug and alcohol dependence · 2014Trial
- The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.Biological psychiatry · 2014Trial
- A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.Drug and alcohol dependence · 2014Trial
- Using prize-based incentives to enhance daily interactive voice response (IVR) compliance: a feasibility study.Journal of substance abuse treatment · 2014Trial
- Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial.Drug and alcohol dependence · 2013Trial
- The Predictive Value of Emotion Regulation in Cocaine Use Disorder Severity: Psychotherapeutic Implications During Hospitalization for Detoxification.Clinical psychology & psychotherapyTrial
- The late positive potential predicts contingency management outcomes for cocaine use disorder.Drug and alcohol dependence · 2025Article
- Cocaine use disorder patients develop distinct patterns of regulation of acth secretion by a vasopressin agonist and oxytocin: Report on a laboratory study.Drug and alcohol dependence reports · 2023Article
- Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.Brain sciences · 2022Review
- Memantine Attenuates Cocaine and neuroHIV Neurotoxicity in the Medial Prefrontal Cortex.Frontiers in pharmacology · 2022Article
- Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?Expert opinion on pharmacotherapy · 2021Review
- Modafinil reduces smoked cocaine self-administration in humans: effects vary as a function of cocaine 'priming' and cost.Drug and alcohol dependence · 2021Article
- Baseline cocaine demand predicts contingency management treatment outcomes for cocaine-use disorder.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Preclinical findings suggest that the inhibition of NMDA glutamatergic neurotransmission may have beneficial effects in the treatment of cocaine dependence. We hypothesized that memantine, a low potency, uncompetitive NMDA receptor antagonist, would be safe and effective in the treatment of cocaine dependence, particularly in preventing relapse to cocaine use in abstinent individuals. Cocaine dependent patients (N=112) were enrolled. The trial began with a 2-week placebo lead-in period during which patients received high-value voucher contingency management to induce abstinence. Participants were then randomized to receive either memantine 20mg bid (N=39) or placebo (N=42) for 12-weeks in combination with individual relapse-prevention therapy. The randomization was stratified by abstinence status during the lead-in period. The primary outcome was the weekly proportion of days of cocaine use. There were no significant differences in cocaine use outcome between the groups treated with memantine versus placebo. Thus, the efficacy of memantine 40 mg/d for the treatment of cocaine dependence was not supported. Urine-confirmed abstinence during the lead-in period was achieved by 44% of participants, and was a strong predictor of subsequent cocaine abstinence during the trial. This suggests that this clinical trial design, an intensive behavioral intervention during a lead-in period, resolves cocaine dependent patients into two subgroups, one that rapidly achieves sustained abstinence and may not need a medication, and another that displays persistent cocaine use and would most likely benefit from a medication to help induce abstinence. Targeting the latter subgroup may advance medication development efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.